OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Targeting doublecortin-like kinase 1 reveals a novel strategy to circumvent chemoresistance and metastasis in ovarian cancer
Samrita Dogra, Sugantha Priya Elayapillai, Dongfeng Qu, et al.
Cancer Letters (2023) Vol. 578, pp. 216437-216437
Open Access | Times Cited: 12
Samrita Dogra, Sugantha Priya Elayapillai, Dongfeng Qu, et al.
Cancer Letters (2023) Vol. 578, pp. 216437-216437
Open Access | Times Cited: 12
Showing 12 citing articles:
Deciphering a GPCR-lncrna-miRNA nexus: Identification of an aberrant therapeutic target in ovarian cancer
Ji Hee Ha, Rangasudhagar Radhakrishnan, Revathy Nadhan, et al.
Cancer Letters (2024) Vol. 591, pp. 216891-216891
Closed Access | Times Cited: 6
Ji Hee Ha, Rangasudhagar Radhakrishnan, Revathy Nadhan, et al.
Cancer Letters (2024) Vol. 591, pp. 216891-216891
Closed Access | Times Cited: 6
BET inhibition decreases HMGCS2 and sensitizes resistant pancreatic tumors to gemcitabine
Aubrey L. Miller, Samuel C. Fehling, Rebecca B. Vance, et al.
Cancer Letters (2024) Vol. 592, pp. 216919-216919
Closed Access | Times Cited: 5
Aubrey L. Miller, Samuel C. Fehling, Rebecca B. Vance, et al.
Cancer Letters (2024) Vol. 592, pp. 216919-216919
Closed Access | Times Cited: 5
A mechanistic, functional, and clinical perspective on targeting CD70 in cancer
Sandeep Kumar, Sowdhamini Mahendiran, Rakesh Sathish Nair, et al.
Cancer Letters (2024) Vol. 611, pp. 217428-217428
Open Access | Times Cited: 4
Sandeep Kumar, Sowdhamini Mahendiran, Rakesh Sathish Nair, et al.
Cancer Letters (2024) Vol. 611, pp. 217428-217428
Open Access | Times Cited: 4
Discovery of novel serum peptide biomarkers for cholangiocarcinoma recurrence through MALDI-TOF MS and LC–MS/MS peptidome analysis
Vasin Thanasukarn, Piya Prajumwongs, Nattha Muangritdech, et al.
Scientific Reports (2025) Vol. 15, Iss. 1
Open Access
Vasin Thanasukarn, Piya Prajumwongs, Nattha Muangritdech, et al.
Scientific Reports (2025) Vol. 15, Iss. 1
Open Access
Octreotide modified liposomes that co-deliver paclitaxel and neferine effectively inhibit ovarian cancer metastasis by specifically binding to the SSTR2 receptors
Yang Liu, Jiahua Wang, Jia-qi Si, et al.
Journal of Drug Delivery Science and Technology (2024) Vol. 98, pp. 105851-105851
Closed Access | Times Cited: 2
Yang Liu, Jiahua Wang, Jia-qi Si, et al.
Journal of Drug Delivery Science and Technology (2024) Vol. 98, pp. 105851-105851
Closed Access | Times Cited: 2
Targeting the PI3K/AKT/mTOR pathway offer a promising therapeutic strategy for cholangiocarcinoma patients with high doublecortin-like kinase 1 expression
Ziwei Liang, Yang Ge, Li Jianjian, et al.
Journal of Cancer Research and Clinical Oncology (2024) Vol. 150, Iss. 7
Open Access | Times Cited: 2
Ziwei Liang, Yang Ge, Li Jianjian, et al.
Journal of Cancer Research and Clinical Oncology (2024) Vol. 150, Iss. 7
Open Access | Times Cited: 2
OKN-007 is an Effective Anticancer Therapeutic Agent Targeting Inflammatory and Immune Metabolism Pathways in Endometrial Cancer.
Sugantha Priya Elayapillai, Anjalika Gandhi, Samrita Dogra, et al.
Journal of Pharmacology and Experimental Therapeutics (2024) Vol. 392, Iss. 1, pp. 100004-100004
Open Access | Times Cited: 2
Sugantha Priya Elayapillai, Anjalika Gandhi, Samrita Dogra, et al.
Journal of Pharmacology and Experimental Therapeutics (2024) Vol. 392, Iss. 1, pp. 100004-100004
Open Access | Times Cited: 2
Mobocertinib antagonizes multidrug resistance in ABCB1- and ABCG2-overexpressing cancer cells: in vitro and in vivo studies
Xing-Duo Dong, Meng Zhang, Qiu‐Xu Teng, et al.
Cancer Letters (2024), pp. 217309-217309
Closed Access | Times Cited: 2
Xing-Duo Dong, Meng Zhang, Qiu‐Xu Teng, et al.
Cancer Letters (2024), pp. 217309-217309
Closed Access | Times Cited: 2
DCLK1 and its oncogenic functions: A promising therapeutic target for cancers
Ye Liu, Beibei Liu, Jingling Huang, et al.
Life Sciences (2023) Vol. 336, pp. 122294-122294
Closed Access | Times Cited: 3
Ye Liu, Beibei Liu, Jingling Huang, et al.
Life Sciences (2023) Vol. 336, pp. 122294-122294
Closed Access | Times Cited: 3
Shake It Up Baby Now: The Changing Focus on TWIST1 and Epithelial to Mesenchymal Transition in Cancer and Other Diseases
Dureali Mirjat, Muhammad Kashif, Cai M. Roberts
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 24, pp. 17539-17539
Open Access | Times Cited: 3
Dureali Mirjat, Muhammad Kashif, Cai M. Roberts
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 24, pp. 17539-17539
Open Access | Times Cited: 3
Evolving Landscape of Detection and Targeting miRNA/Epigenetics for Therapeutic Strategies in Ovarian Cancer
Arpan Dey Bhowmik, Pallab Shaw, Mohan Shankar Gopinatha Pillai, et al.
Cancer Letters (2024) Vol. 611, pp. 217357-217357
Closed Access
Arpan Dey Bhowmik, Pallab Shaw, Mohan Shankar Gopinatha Pillai, et al.
Cancer Letters (2024) Vol. 611, pp. 217357-217357
Closed Access
Regulation of ovarian cancer by protein post-translational modifications
Qiugang Zhu, Huimin Zhou, Feiting Xie
Frontiers in Oncology (2024) Vol. 14
Open Access
Qiugang Zhu, Huimin Zhou, Feiting Xie
Frontiers in Oncology (2024) Vol. 14
Open Access
